LEO Pharma develops, manufactures and markets pharmaceutical drugs to dermatologic and thrombotic patients in more than 100 countries globally. The company is headquartered in Denmark and is wholly owned by the LEO Foundation.
Contact:
Address: Marynarska 15 02-674 Warsaw
Tel.: (+48) 22 244 18 40
Website: http://www.leo-pharma.pl/
Email: LZWPL@leo-pharma.com
Poland has an important manufacturing role for the CEE region and this is where Mylan has settled Agila, a state-of-the-art, high quality injectables manufacturing platform. Mylan has great ambitions in…
GSK Poland’s General Manager, Jerzy Toczyski, explains the reasons behind acquiring a state-of-the-art manufacturing facility in Poland, as well as the need to implement leaner manufacturing processes to become more…
GSK Poland’s General Manager, Jerzy Toczyski, explains the reasons behind acquiring a state-of-the-art manufacturing facility in Poland, as well as the need to implement leaner manufacturing processes to become more…
GSK Poland’s General Manager, Jerzy Toczyski, explains the reasons behind acquiring a state-of-the-art manufacturing facility in Poland, as well as the need to implement leaner manufacturing processes to become more…
Selvita is one of Poland’s R&D jewels, and its co-founder and CEO, Paweł Przewięźlikowski, strongly wishes that others would join their efforts in finally raising Poland’s footprint in R&D. He…
Selvita is one of Poland’s R&D jewels, and its co-founder and CEO, Paweł Przewięźlikowski, strongly wishes that others would join their efforts in finally raising Poland’s footprint in R&D. He…
Selvita is one of Poland’s R&D jewels, and its co-founder and CEO, Paweł Przewięźlikowski, strongly wishes that others would join their efforts in finally raising Poland’s footprint in R&D. He…
Sanofi’s General Manager in Poland, Marynika Woroszylska-Sapieha, shares two very important concepts that showcase the situation in Poland, stating that: “The biggest obstacle to innovation in Poland is the threshold…
“Average pharmaceutical company expenditures on R&D are in the range of 13 to 15 percent of revenues: much higher than the global average, and much higher than other Polish industrial…
“The swelling influence of wholesalers in the market frightens me.” With three wholesalers in Poland holding 80 percent of the market and establishing their own brands in a changing environment,…
“Instead of creating a state pharmaceutical duopoly, we have created an environment where the pharma industry can introduce new products and market them enthusiastically. This creates a market where pharmaceutical…
Persistence is a blessing, explains Glenmark’s Country Manager for Poland, Andrzej Gondek. By adapting a new product strategy to increase their OTC portfolio, Glenmark managed to nearly double its sales…
See our Cookie Privacy Policy Here
